Mogrify® has developed a proprietary suite of platform technologies that utilize big-data and advanced computational modeling to enable direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.Since establishing R&D operations in 2019 Mogrify Limited have focused on further improving the predictive capability of the platform with supportive transcription factor vector technology and cell based screening platforms. We are now developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need. The CSO’s role is to lead advancement of these therapeutic programs in areas including otology, ophthalmology and diabetes toward and into clinical development.

The Cell and Gene Therapy Catapult is funded by both government grants (IUK) and Industry via collaborative and commercial research and development projects. Our role is to promote growth of the cell and gene therapy (ATMP) industry. We are an organisation of over four hundred staff working in all elements of the cell and gene therapy landscape from process and analytical development at our London site, supporting companies doing GMP grade manufacture in our Stevenage site and also working within the UK ATMP ecosystem to support skill development and adoption of novel therapeutic modalities.

As Chief Scientific Officer for cell and gene therapy in GSK's Rare Diseases Unit I led the development and regulatory review of Strimvelis, the first CD34 Stem Cell Gene Therapy to be licensed anywhere in the world. I also led (for 2 years) the development of a similar gene therapy project for a disease called Metachromatic Leukodystrophy. Both of these programmes were ultimately outlicensed to Orchard Therapeutics in 2018, a transaction that I was involved in shaping and delivering. Whilst in the Rare Diseases unit I was Scientific Adviser on new business opportunities for cell and gene therapy and acted as a rotating member of GSK's Technology Investment Board.Prior to taking the role in rare diseases I worked in a business development function, finding new drug discovery technologies, constructing alliances and managing those alliances. I have 25 years experience of R&D and have worked in all phases of development from target identification through to phase IV in a broad range of therapeutic areas.